Ryan & Maniskas, LLP Announces Investigation of SeraCare Life Sciences Inc.
14 Febrero 2012 - 10:09AM
Business Wire
Ryan & Maniskas, LLP (www.rmclasslaw.com/cases/srls) is
investigating potential claims against the board of directors of
SeraCare Life Sciences Inc. (“SeraCare” or the “Company”) (NASDAQ:
SRLS) concerning possible breaches of fiduciary duty and other
violations of law related to the Company’s efforts to sell SeraCare
to an affiliate of Linden Capital Partners in a transaction valued
at approximately $82 million.
Our investigation concerns possible breaches of fiduciary duty
and other violations of law related to the approval of the
transaction by Company’s board of directors; in particular, whether
the Company undertook a fair process to obtain fair consideration
for all shareholders of SeraCare. For more information regarding
our investigation, please contact Ryan & Maniskas, LLP (Richard
A. Maniskas, Esquire) toll-free at (877) 316-3218 or by email at
rmaniskas@rmclasslaw.com or visit:
www.rmclasslaw.com/cases/srls.
Under the terms of the transaction, SeraCare shareholders will
receive $4.00 per share.
If you own shares of SeraCare and would like to learn more about
these claims or if you wish to discuss these matters and have any
questions concerning this announcement or your rights, contact
Richard A. Maniskas, Esquire toll-free at (877) 316-3218 or to sign
up online, visit: www.rmclasslaw.com/cases/srls. You may also email
Mr. Maniskas at rmaniskas@rmclasslaw.com. For more information
about class action cases in general, please visit our website:
www.rmclasslaw.com.
Ryan & Maniskas, LLP is a national shareholder litigation
firm. Ryan & Maniskas, LLP is devoted to protecting the
interests of individual and institutional investors in shareholder
actions in state and federal courts nationwide.
Seracare Life Sciences (NASDAQ:SRLS)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Seracare Life Sciences (NASDAQ:SRLS)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Seracare Life Sciences (MM) (NASDAQ): 0 recent articles
Más de Ryan & Maniskas, LLP Artículos de Noticias